Reported Earnings • Mar 27
Full year 2025 earnings released: US$0.10 loss per share (vs US$0.14 loss in FY 2024) Full year 2025 results: US$0.10 loss per share (improved from US$0.14 loss in FY 2024). Revenue: US$10.5m (up 61% from FY 2024). Net loss: US$1.38m (loss narrowed 26% from FY 2024). Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 10% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Bekanntmachung • Mar 24
Itaconix plc, Annual General Meeting, May 14, 2026 Itaconix plc, Annual General Meeting, May 14, 2026. Location: fieldfisher llp, 9th floor, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdom Bekanntmachung • Mar 11
Itaconix plc to Report Fiscal Year 2025 Results on Mar 24, 2026 Itaconix plc announced that they will report fiscal year 2025 results on Mar 24, 2026 New Risk • Sep 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Market cap is less than US$100m (UK£14.8m market cap, or US$19.8m). Reported Earnings • Sep 16
First half 2025 earnings released: US$0.03 loss per share (vs US$0.076 loss in 1H 2024) First half 2025 results: US$0.03 loss per share (improved from US$0.076 loss in 1H 2024). Revenue: US$4.82m (up 73% from 1H 2024). Net loss: US$410.0k (loss narrowed 60% from 1H 2024). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 18% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings. New Risk • Sep 15
New major risk - Revenue and earnings growth Earnings have declined by 19% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 19% per year over the past 5 years. Minor Risk Market cap is less than US$100m (UK£17.5m market cap, or US$23.9m). Bekanntmachung • Sep 04
Itaconix plc to Report First Half, 2025 Results on Sep 15, 2025 Itaconix plc announced that they will report first half, 2025 results on Sep 15, 2025 Bekanntmachung • Jul 02
Itaconix plc Announces the Commercial Product Launch of BIO*Asterix Itaconix plc announced the commercial product launch of BIOAsterix®?, a new line of plant-based functional building blocks for polymeric binders used in paints, coatings, and adhesives. The BIOAsterix products are specialty derivatives of itaconic acid that can fully or partially replace fossil-based acrylate, methacrylate, or styrene monomers in a wide range of resins and composites. The initial BIOAsterix offering consists of three products, including one new patented monomer, which are positioned as safer and more sustainable alternatives in the $2.6 billion market for butyl acrylates in Europe and North America. The Company plans to offer an extensive and comprehensive line of itaconate alternatives by adding additional proprietary and non-proprietary products to the BIOAsterix catalog in the future. Initial ecommerce customers are expected to come from North American academic and industry laboratories that are developing paths for safer and more sustainable polymers. The Company developed specialty itaconate derivatives that represent the beginning of a long-term growth initiative and future revenue opportunity for Itaconix. Commercial efforts over the last few years focused on specific usage with a limited number of potential customers. This new commercial product launch and use of ecommerce are expected to generate broader opportunities within the large and diverse paints and coatings segment of the acrylic acid market. Bekanntmachung • May 05
Itaconix plc, Annual General Meeting, May 08, 2025 Itaconix plc, Annual General Meeting, May 08, 2025. Location: fieldfisher llp, 9th floor, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdom New Risk • Apr 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$0 net loss next year). Share price has been volatile over the past 3 months (7.3% average weekly change). Market cap is less than US$100m (UK£15.5m market cap, or US$20.3m). Reported Earnings • Mar 31
Full year 2024 earnings released: US$0.001 loss per share (vs US$0.12 loss in FY 2023) Full year 2024 results: US$0.001 loss per share. Revenue: US$6.50m (down 17% from FY 2023). Net loss: US$1.87m (loss widened 21% from FY 2023). Revenue is expected to fall by 149% p.a. on average during the next 2 years compared to a 2.4% decline forecast for the Chemicals industry in the United Kingdom. New Risk • Mar 30
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Currently unprofitable and not forecast to become profitable next year (US$0 net loss next year). Market cap is less than US$100m (UK£15.1m market cap, or US$19.6m). Bekanntmachung • Mar 18
Itaconix plc to Report Fiscal Year 2024 Results on Mar 31, 2025 Itaconix plc announced that they will report fiscal year 2024 results on Mar 31, 2025 Bekanntmachung • Oct 16
Itaconix plc Announces Launch of the Itaconix SPARX Program Itaconix plc announced the launch of its SPARX program - a new collaborative initiative to increase the value and reduce the time-to-market for safer, better performing, and more sustainable home and personal care products. Itaconix developed the SPARX program in response to brands seeking new innovations to meet consumer desires for affordable products that perform better and are better for the world. As an extension of its existing formulated solutions work, the Company sees opportunities in a series of home and personal care product categories for new offerings that deliver excellent performance while using safer ingredients, more sustainable materials, less chemicals, and less plastic. The SPARX program will integrate the efforts of Itaconix and other advanced specialty ingredient companies with innovative end-product manufacturers and purpose-driven brands to speed the introduction of new generations of consumer products. The program has a goal for brands to introduce at least 10 new products by the end of 2025. The Company expects to announce SPARX collaborations with ingredient suppliers, contract manufacturers, and brands in the coming months towards achieving this goal. SPARX is being introduced by Itaconix at the annual SEPAWA® CONGRESS being held in Berlin (16-18 October). SEPAWA® is one of the most influential annual gatherings within the European and North American home detergent and cleaning industry. New Risk • Sep 16
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (9.5% average weekly change). Minor Risk Market cap is less than US$100m (UK£19.8m market cap, or US$26.1m). Bekanntmachung • Sep 02
Itaconix plc to Report First Half, 2024 Results on Sep 10, 2024 Itaconix plc announced that they will report first half, 2024 results on Sep 10, 2024 Bekanntmachung • Jul 16
Itaconix plc Reiterates Earnings Guidance for the First Six Months of 2024 Itaconix plc reiterated earnings guidance for the first six months of 2024. For the months, the company expected its revenue expectations of $6 million to $6.5 million and gross profit margin expectations of 36% for Fiscal Year 2024. Bekanntmachung • Apr 30
Itaconix plc Launches Two New Plant-Based Performance Ingredients for Household Detergents and Cleaners Itaconix plc announced the launch of two new ingredients for improving the performance of household detergent formulations. The new products represent major advances in phosphate replacement with new multi-functional performance from plant-based materials that are safe for the environment. Itaconix®? TSI®? 422 is the latest and most advanced addition to Itaconix's revolutionary line of multi-functional ingredients for eliminating the detrimental effects of hard water in detergent and industrial applications. Itaconix TSI 422 extends the performance advantages of the Itaconix TSI 322, particularly in dishwashing detergents. Major benefits include better scale inhibition and more compact dosing while maintaining high plant-based content. Itaconix®? ONZ™? 405 is a new powder version of Itaconix's innovative line of liquid plant-based ingredients that add both fast-acting odor neutralization and excellent scale inhibition to detergents and cleaners. The new powder form extends the potential for new performance claims into important consumer product categories such as powder laundry additives and plastic-free detergent concentrates. Bekanntmachung • Apr 17
Itaconix plc Provides Revenue Guidance for the Year 2024 Itaconix plc provided revenue guidance for the year 2024. For the period, Company expects lower revenues due to not reaching satisfactory commercial terms with an existing North American detergent merchandizing customer following extensive negotiations. Bekanntmachung • Apr 16
Itaconix plc, Annual General Meeting, May 20, 2024 Itaconix plc, Annual General Meeting, May 20, 2024, at 13:00 Coordinated Universal Time. Location: Fieldfisher LLP, 9th Floor, Riverbank House, 2 Swan Lane, London United Kingdom Reported Earnings • Apr 15
Full year 2023 earnings released: US$0.12 loss per share (vs US$0.28 loss in FY 2022) Full year 2023 results: US$0.12 loss per share (improved from US$0.28 loss in FY 2022). Revenue: US$7.87m (up 41% from FY 2022). Net loss: US$1.54m (loss narrowed 38% from FY 2022). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 2.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 29% per year, which means it is performing significantly worse than earnings. Bekanntmachung • Apr 08
Itaconix plc to Report Fiscal Year 2023 Results on Apr 15, 2024 Itaconix plc announced that they will report fiscal year 2023 results on Apr 15, 2024 New Risk • Apr 02
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable next year (US$0 net loss next year). Market cap is less than US$100m (UK£26.3m market cap, or US$33.1m). New Risk • Mar 30
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable next year (US$0 net loss next year). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (UK£35.3m market cap, or US$44.6m). Bekanntmachung • Feb 09
Itaconix plc Appoints Jonathan Brooks as Independent Non-Executive Director Itaconix plc announced the appointment of Jonathan Brooks to the Board as an independent Non-Executive Director. Jonathan is recently retired from the European law firm Fieldfisher LLP where he was a Partner in its highly regarded Equity Capital Markets practice. Prior to joining Fieldfisher, he was a Partner and Head of the Capital Markets Group at Maclay Murray & Spens LLP, having qualified as a solicitor and subsequently becoming a Partner at Boodle Hatfield LLP. With over 35 years of experience, Jonathan has acted for clients in a diverse range of industries, including technology, materials, healthcare, natural resources, renewable energy, and financial services. His experience extends across key corporate growth activities, serving as a valued advisor in numerous IPOs, fundraisings, and venture capital investments. He has managed transactions and advised on legal, regulatory, corporate governance and sustainability matters for a range of high-growth companies in the global equity capital markets. Bekanntmachung • Dec 07
Itaconix plc Provides Earning Guidance for the Year 2023 , Fiscal Year 2024 and for Fiscal Year 2025 Itaconix plc provided earning guidance for the Year 2023, Fiscal Year 2024 and for Fiscal year 2025. For the year 2023 company expects revenues to be at least $7.7 Million, with Fiscal year 2023 earnings expected to be in line with current market expectations.For the Fiscal year 2024, revenue expectations are revised to $9.5 Million or more For the fiscal year 2025, company expects revenue of $12.5 Million or more, with no change to earnings expectations. Reported Earnings • Sep 17
First half 2023 earnings released: US$0.054 loss per share (vs US$0.13 loss in 1H 2022) First half 2023 results: US$0.054 loss per share (improved from US$0.13 loss in 1H 2022). Revenue: US$4.03m (up 32% from 1H 2022). Net loss: US$694.0k (loss narrowed 38% from 1H 2022). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 6.4% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings. Bekanntmachung • Sep 05
Itaconix plc to Report First Half, 2023 Results on Sep 12, 2023 Itaconix plc announced that they will report first half, 2023 results on Sep 12, 2023 New Risk • Jun 12
New major risk - Negative shareholders equity The company has negative equity. Total equity: -US$775k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$278k free cash flow). Negative equity (-US$775k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$697k net loss in 3 years). Shareholders have been diluted in the past year (50% increase in shares outstanding). Market cap is less than US$100m (UK£31.0m market cap, or US$39.0m). Reported Earnings • Jun 05
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2022 results: US$0.50 loss per share (further deteriorated from US$0.001 loss in FY 2021). Revenue: US$5.60m (up 116% from FY 2021). Net loss: US$2.46m (loss widened 441% from FY 2021). Revenue missed analyst estimates by 1.6%. Earnings per share (EPS) exceeded analyst estimates by 2.9%. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 6.6% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 245 percentage points per year, which is a significant difference in performance. Bekanntmachung • Jan 05
Itaconix plc Announces Board Changes Itaconix plc announced changes to the Board. Paul LeBlanc is appointed to the Board as an independent Non-Executive Director and Chair of the Audit Committee with effect from January 5, 2023. He is Chief Financial Officer and Treasurer of Bemis Associates Inc, a global manufacturer of specialty films and adhesives for the apparel and industrial markets. He joined Bemis in 1999 as Controller and assumed increasing levels of responsibility during Bemis' rapid growth into a global manufacturer, including overseeing the acquisition and integration of operations in Europe and Asia. He earned his Bachelor of Science in Accounting from Thomas College and his Master of Business Administration from University of Massachusetts, Dartmouth. In addition, Dr. Peter Nieuwenhuizen, the Company's Non-Executive Interim Chair, who joined the Board in July 2022, now takes the role of Non-Executive Chair on a permanent basis and with effect from January 5, 2023. The Board now comprises Dr. Peter Nieuwenhuizen (Non-Executive Chair), Paul LeBlanc (Non-Executive Director), John R. Shaw (Chief Executive Officer), and Laura Denner (Chief Financial Officer). Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Nee Baiz Gmunder was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 15
First half 2022 earnings released: US$0.003 loss per share (vs US$0 in 1H 2021) First half 2022 results: US$0.003 loss per share (further deteriorated from US$0 in 1H 2021). Revenue: US$3.06m (up 124% from 1H 2021). Net loss: US$1.12m (loss widened US$941.0k from 1H 2021). Revenue is forecast to grow 43% p.a. on average during the next 2 years, compared to a 8.0% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 97% per year but the company’s share price has only increased by 38% per year, which means it is significantly lagging earnings growth. Board Change • Jul 24
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Nee Baiz Gmunder was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Breakeven Date Change • Jun 09 The analyst covering Itaconix previously expected the company to break even in . New forecast suggests the company will make a profit of US$0 in .
Reported Earnings • Jun 09
Full year 2021 earnings: EPS and revenues exceed analyst expectations Full year 2021 results: US$0.001 loss per share (up from US$0.005 loss in FY 2020). Revenue: US$2.60m (down 21% from FY 2020). Net loss: US$455.0k (loss narrowed 72% from FY 2020). Revenue exceeded analyst estimates by 6.1%. Earnings per share (EPS) also surpassed analyst estimates by 66%. Over the next year, revenue is forecast to grow 81% compared to a 15% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 118% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth. Board Change • May 31
High number of new directors Independent Non-Executive Director Nee Baiz Gmunder was the last director to join the board, commencing their role in 2022. Board Change • Apr 27
High number of new directors Independent Non-Executive Director Nee Baiz Gmunder was the last director to join the board, commencing their role in 2022. Board Change • Mar 21
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. CEO & Director John Shaw was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Bekanntmachung • Oct 03
Itaconix plc Announces Retirement of Mike Townend as A Non-Executive Director Itaconix plc announced that Mike Townend stepped down as a Non-Executive Director after many years of dedicated service to the Company.